CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
改变递送技术以优化 CAR 治疗的策略
英文原题：Strategies for Altering Delivery Technologies to Optimize CAR Therapy.
查看英文原题
Strategies for Altering Delivery Technologies to Optimize CAR Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已被证实可有效治疗血液系统恶性肿瘤。目前亟待解决的问题之一是如何高效、快速、安全地制备CAR-T 细胞。实体瘤中工程化T细胞的持久性和活性仍需进一步增强，T细胞穿透肿瘤微环境的策略也有待改善。此外，尽管以T细胞生物学为主因的相关问题正逐渐得到解决，CAR-T 细胞的制造模式和工艺仍需改进，以确保该疗法能够广泛应用。本文总结了若干可提高CAR-T 细胞疗效的策略。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective strategy for the treatment of hematological malignancies. At present, how to prepare CAR-T cells efficiently, quickly, and safely is one of the urgent problems to be solved. The durability and activity of engineered T cells in solid tumors need to be further improved, and the strategy of T cells penetrating the tumor microenvironment also needs to be improved.
In addition, although the problems mainly caused by T-cell biology are being solved, the manufacturing mode and process still need to be improved to ensure that CAR-T cell therapy can be widely used. This paper summarizes some strategies that can improve the efficacy of CAR-T cells.
论文信息
- 作者
- Cao L、Liu Y、Lin G
- 第一作者单位
- Student Counseling Center, Shandong University, Jinan 250012, China.China
- 通讯作者单位
- School of Pharmaceutical Science, Shandong University, Jinan 250012, China.China
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2025 Mar 30
- 原文标识
- PubMed 40244018 · DOI 10.3390/ijms26073206
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →